Evaluation of Liraglutide 3.0mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 Response
Status:
Completed
Trial end date:
2020-06-11
Target enrollment:
Participant gender:
Summary
A double-blinded, randomised, placebo-controlled trial of liraglutide 3.0 mg in patients with
poor weight-loss and a suboptimal glucagon-like peptide-1 response following bariatric
surgery